In recent years, we've seen automated external defibrillators (AED) distributed in high-traffic areas throughout many of our communities. Though more cases of sudden cardiac events are occurring outside the home-owing to greater mobility for our older, at-risk patients-a great many cases do still occur in the home. With this in mind, researchers postulated that an AED placed in the home of an at-risk patient may limit their vulnerability to a sudden cardiac event. What did they find? Dr. Gust Bardy, president of the Seattle Institute for Cardiac Research and lead investigator of the Home Automated External Defibrillator Trial (HAT), published in the New England Journal of Medicine, discusses the findings of this trial with host Dr. Matthew Sorrentino.
Automated External Defibrillators at Home?
Ready to Claim Your Credits?
You have attempts to pass this post-test. Take your time and review carefully before submitting.
Good luck!
Overview
In recent years, we've seen automated external defibrillators (AED) distributed in high-traffic areas throughout many of our communities. Though more cases of sudden cardiac events are occurring outside the home-owing to greater mobility for our older, at-risk patients-a great many cases do still occur in the home. With this in mind, researchers postulated that an AED placed in the home of an at-risk patient may limit their vulnerability to a sudden cardiac event. What did they find? Dr. Gust Bardy, president of the Seattle Institute for Cardiac Research and lead investigator of the Home Automated External Defibrillator Trial (HAT), published in the New England Journal of Medicine, discusses the findings of this trial with host Dr. Matthew Sorrentino.
Title
Share on ReachMD
CloseProgram Chapters
Segment Chapters
Playlist:
Recommended
Phase 3 study results of plozasiran in patients with FCS
Advances in MASLD/MASH: Treating the Liver, the Disease, and the Patient – Chair’s Perspective
Love Story: Lipid Education for Women’s Heart Health
Biomarkers of the Storm: Decoding IRI’s Signature
HF Management for Patients with Comorbid Conditions
Rozanolixizumab for Myasthenia Gravis: An Alternative to Corticosteroids
Analysis of Patients With and Without AF Living With HFmrEF/HFpEF: FINEARTS-HF
Effect of Finerenone on NT-proBNP in HFmrEF/HFpEF: FINEARTS-HF Trial
We’re glad to see you’re enjoying ReachMD…
but how about a more personalized experience?